Vertex Pharma (VRTX) Tops Q2 EPS by 3c, raises guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $547.65 +0.57%
Revenue Growth %: +10.7%
Financial Fact:
Net loss attributable to Vertex: -38.84M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Revenue Growth %: +10.7%
Financial Fact:
Net loss attributable to Vertex: -38.84M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $3.89, $0.03 better than the analyst estimate of $3.86. Revenue for the quarter came in at $2.49 billion versus the consensus estimate of $2.42 billion.
Guidance:
Company raises full year 2023 product revenue guidance to $9.7 to $9.8 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Adjust Monthly US Director's Cut List
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- Palo Alto Networks (PANW) Tops Q4 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
